Incannex is a clinical-stage biopharmaceutical company developing oral combination drug therapies and psychedelic-assisted treatments for serious chronic conditions. The company is pre-revenue with no approved products, focusing entirely on clinical development and regulatory progress. Its lead drug candidate, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea. IHL-42X has received FDA Fast Track designation and is undergoing Phase 2 dose-optimization trials ahead of Phase 3. Its second clinical program, PSX-001, combines oral synthetic psilocybin with structured psychological therapy for generalized anxiety disorder. Incannex also holds IHL-675A for inflammatory conditions, though development is currently on hold. Incannex uses the FDA 505(b)(2) regulatory pathway for its combination drug candidates to leverage existing safety data from approved components. The company relies on third-party manufacturers and contract research organizations to execute its clinical trials. Incannex plans to commercialize approved therapies first in the U.S. before expanding internationally, while maintaining flexibility to pursue licensing and collaboration agreements.